ethyl 4-[(5-fluoro-2-nitrophenyl)amino]-1-piperidinecarboxylate | 850697-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-[(5-fluoro-2-nitrophenyl)amino]-1-piperidinecarboxylate
• 英文别名: ethyl 4-(5-fluoro-2-nitroanilino)piperidine-1-carboxylate
• CAS: 850697-56-2
• 化学式: C₁₄H₁₈FN₃O₄
• 分子量: 311.313
• InChiKey: DILKJYYQCWFUFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-[(5-fluoro-2-nitrophenyl)amino]-1-piperidinecarboxylate 在 盐酸 、 锌 作用下， 以 甲醇 、 水 为溶剂， 生成 ethyl 4-[(2-amino-5-fluorophenyl)amino]-1-piperidinecarboxylate
  参考文献：
  名称：

  M1变构激动剂TBPB的类似物的合成和SAR。第一部分：探索替代的苄基和特权结构部分。

  摘要：

  这封信描述了通过高度重复的M1变构激动剂TBPB的类似物通过迭代类似物库方法开发的合成和SAR的首次描述。在轻微的结构变化下，仍保持了mAChR选择性，但是部分M1激动的程度变化很大。

  DOI：

  10.1016/j.bmcl.2008.09.023
• 作为产物：
  描述：

  2,5-二氟硝基苯 、 4-氨基-1-哌啶甲酸乙酯 在 potassium carbonate 、 sodium iodide 作用下， 以 异丁酰胺 为溶剂， 反应 3.5h， 以98%的产率得到ethyl 4-[(5-fluoro-2-nitrophenyl)amino]-1-piperidinecarboxylate
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  [FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2008108958A8

文献信息

• Benzimidazolones Which Have Activity at M1 Receptor
  申请人：Budzik Brian

  公开号：US20080306112A1

  公开（公告）日：2008-12-11

  Compounds of formula (I) and salts are provided: wherein R 6 is selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, C 1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C 1-6 alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了化学式（I）和盐的化合物：其中R6选择自氢，卤素，C1-6烷基，C1-6烷基取代一个或多个氟原子，C3-6环烷基，C3-6环烷基取代一个或多个氟原子，C1-6烷氧基，C1-6烷氧基取代一个或多个氟原子和氰基，Q为氢或C1-6烷基。这些化合物是M1受体激动剂，可用于治疗精神障碍和认知障碍等疾病。
• Benzimidazolones which have activity at M1 receptor
  申请人：Glaxo Group Limited

  公开号：US08288413B2

  公开（公告）日：2012-10-16

  Compounds of formula (I) and salts are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了式（I）化合物和盐： 其中R6从氢，卤素，C1-6烷基，C1-6烷基取代一个或多个氟原子，C3-6环烷基，C3-6环烷基取代一个或多个氟原子，C1-6烷氧基，C1-6烷氧基取代一个或多个氟原子和氰基中选择，Q为氢或C1-6烷基。这些化合物是M1激动剂，并且在治疗精神障碍和认知障碍等方面非常有用。
• WO2007/36711
  申请人：——

  公开号：——

  公开（公告）日：——
• Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine
  作者：Christopher S. Burgey、Craig A. Stump、Diem N. Nguyen、James Z. Deng、Amy G. Quigley、Beth R. Norton、Ian M. Bell、Scott D. Mosser、Christopher A. Salvatore、Ruth Z. Rutledge、Stefanie A. Kane、Kenneth S. Koblan、Joseph P. Vacca、Samuel L. Graham、Theresa M. Williams

  DOI：10.1016/j.bmcl.2006.07.044

  日期：2006.10

  In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented. (c) 2006 Elsevier Ltd. All rights reserved.
• Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors
  作者：Darin J. Gustin、Clark A. Sehon、Jianmei Wei、Hui Cai、Steven P. Meduna、Haripada Khatuya、Siquan Sun、Yin Gu、Wen Jiang、Robin L. Thurmond、Lars Karlsson、James P. Edwards

  DOI：10.1016/j.bmcl.2005.01.045

  日期：2005.3

  A novel series of competitive, reversible cathepsin S (Cats) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of Cats inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S. (c) 2005 Elsevier Ltd. All rights reserved.